{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=16",
    "query": {
      "condition": "Safety Study",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 33591,
    "total_pages": 3360,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T07:35:10.784Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01009086",
      "title": "A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Psoriatic"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 45 mg",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 90 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 615,
      "start_date": "2009-12",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2015-03-03",
      "last_synced_at": "2026-11-19T07:35:10.784Z",
      "location_count": 26,
      "location_summary": "Encinitas, California • La Jolla, California • San Diego, California + 23 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Trumbull",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01009086"
    },
    {
      "nct_id": "NCT07225686",
      "title": "Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity",
        "Obstructive Sleep Apnea"
      ],
      "interventions": [
        {
          "name": "Maridebart cafraglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 250,
      "start_date": "2025-12-19",
      "completion_date": "2028-07-21",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-11-19T07:35:10.784Z",
      "location_count": 13,
      "location_summary": "Northridge, California • Rolling Hills Estates, California • Brandon, Florida + 10 more",
      "locations": [
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Palmetto Bay",
          "state": "Florida"
        },
        {
          "city": "Pompano Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07225686"
    },
    {
      "nct_id": "NCT00658970",
      "title": "Evaluation of KX2-391 in Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "KX2-391",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Athenex, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2007-11",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2011-06-08",
      "last_synced_at": "2026-11-19T07:35:10.784Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00658970"
    },
    {
      "nct_id": "NCT00394173",
      "title": "Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Irritable Bowel Syndrome With Diarrhea (IBS-D)"
      ],
      "interventions": [
        {
          "name": "DNK333",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 180,
      "start_date": "2006-09",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2017-02-27",
      "last_synced_at": "2026-11-19T07:35:10.784Z",
      "location_count": 37,
      "location_summary": "Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00394173"
    },
    {
      "nct_id": "NCT03742973",
      "title": "A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Biliary Cholangitis"
      ],
      "interventions": [
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2019-03-28",
      "completion_date": "2019-09-26",
      "has_results": true,
      "last_update_posted_date": "2020-10-14",
      "last_synced_at": "2026-11-19T07:35:10.784Z",
      "location_count": 10,
      "location_summary": "Coronado, California • Sacramento, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03742973"
    },
    {
      "nct_id": "NCT06062069",
      "title": "A Study of CT-868 in Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Overweight",
        "Obese",
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "CT-868",
          "type": "DRUG"
        },
        {
          "name": "CT-868 Pen Injector",
          "type": "DEVICE"
        },
        {
          "name": "CT-868 Pen Injector, Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Carmot Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2023-11-27",
      "completion_date": "2025-07-07",
      "has_results": true,
      "last_update_posted_date": "2026-10-28",
      "last_synced_at": "2026-11-19T07:35:10.784Z",
      "location_count": 22,
      "location_summary": "Concord, California • Escondido, California • Aurora, Colorado + 17 more",
      "locations": [
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06062069"
    },
    {
      "nct_id": "NCT02035696",
      "title": "Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Trivalent influenza vaccine (TIVc)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trivalent influenza vaccine-licensed",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "48 Months",
        "sex": "ALL",
        "summary": "6 Months to 48 Months"
      },
      "enrollment_count": 671,
      "start_date": "2013-12",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2018-07-10",
      "last_synced_at": "2026-11-19T07:35:10.784Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Ontario",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02035696"
    },
    {
      "nct_id": "NCT06598462",
      "title": "A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Eosinophilic Esophagitis (EoE)"
      ],
      "interventions": [
        {
          "name": "Solrikitug Low Dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Solrikitug Mid Dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Solrikitug High Dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Uniquity One (UNI)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 184,
      "start_date": "2024-10-16",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-20",
      "last_synced_at": "2026-11-19T07:35:10.784Z",
      "location_count": 38,
      "location_summary": "Dothan, Alabama • Glendale, Arizona • Peoria, Arizona + 35 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06598462"
    },
    {
      "nct_id": "NCT01224262",
      "title": "A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LIQ001 (0.45mg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LIQ001 (1.8mg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Liquidia Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 152,
      "start_date": "2010-09",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2013-03-01",
      "last_synced_at": "2026-11-19T07:35:10.784Z",
      "location_count": 1,
      "location_summary": "Melbourne, Florida",
      "locations": [
        {
          "city": "Melbourne",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01224262"
    },
    {
      "nct_id": "NCT06695988",
      "title": "Time-restricted Eating Acceptability, Efficacy and Safety in Obesity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Time Restricted Eating",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Time Restricted Eating",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Mississippi, Oxford",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 44,
      "start_date": "2024-06-18",
      "completion_date": "2025-08-28",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-19T07:35:10.784Z",
      "location_count": 1,
      "location_summary": "Oxford, Mississippi",
      "locations": [
        {
          "city": "Oxford",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06695988"
    }
  ]
}